BAD and neoplasm: We also investigated total Bad and phospho-Bad levels in normal and tumor tissues of ER/PR + Her2-, ER/PR + Her2+, ER/PR-Her2+ and ER/PR-HER2- breast cancer patients (Fig. 4b).